Zoetis (NYSE:ZTS) Reports Q4 CY2025 Revenue Surpassing Expectations

Zoetis Reports Strong Q4 2025 Results

Zoetis (NYSE:ZTS), a leader in animal health, posted fourth-quarter 2025 revenue of $2.39 billion, marking a 3% increase from the previous year and surpassing market expectations. The company projects its annual revenue to reach approximately $9.93 billion, closely aligning with analyst forecasts. Adjusted earnings per share came in at $1.48, exceeding consensus estimates by 5.5%.

Curious if Zoetis is a smart investment right now?

Highlights from Zoetis Q4 2025

• Revenue: $2.39 billion, topping analyst projections of $2.37 billion (3% year-over-year growth, 0.8% above expectations)
• Adjusted EPS: $1.48, beating analyst consensus of $1.40 (5.5% above estimates)
• 2026 Adjusted EPS Guidance: Midpoint forecast of $7.05, 3.3% higher than analyst expectations
• Operating Margin: 31.9%, a slight decrease from 32.9% in the prior year’s quarter
• Market Cap: $56.7 billion

“Zoetis delivered a robust performance in 2025, showcasing the durability and breadth of our portfolio across different species, regions, and distribution channels. Our leading brands and categories continued to drive growth, even as we managed a rapidly changing business landscape,” commented CEO Kristin Peck.

About Zoetis

Zoetis (NYSE:ZTS) originated as a spin-off from Pfizer in 2013 and has since become the world’s largest dedicated animal health company. The business develops and markets medicines, vaccines, diagnostics, and services for both companion animals and livestock globally.

Evaluating Revenue Trends

Consistent sales growth is often a hallmark of a high-quality company. While any business can have a few strong quarters, sustained expansion is more telling. Over the past five years, Zoetis achieved a compound annual growth rate (CAGR) of 7.2% in revenue—a moderate pace compared to other healthcare firms, but still notable.

Although long-term growth is crucial, recent performance can reveal shifts in demand or innovation cycles. In the last two years, Zoetis’s annualized revenue growth slowed to 5.3%, trailing its five-year average. Such deceleration can be a warning sign in healthcare, where customer preferences may shift quickly and switching costs are low.

This quarter, Zoetis delivered a 3% year-over-year revenue increase, narrowly beating Wall Street’s projections by 0.8%.

Looking forward, analysts anticipate revenue growth of 4.9% over the next year, which is in line with recent trends. While this outlook is modest, Zoetis continues to demonstrate financial stability in other areas.

Profitability and Operating Margins

Over the last five years, Zoetis has consistently delivered strong profitability, maintaining an average operating margin of 36%—an impressive figure for the healthcare sector.

Examining profitability trends, Zoetis’s operating margin improved by 1.5 percentage points over five years, benefiting from operational leverage as sales grew. Most of this progress has occurred in the last two years.

In the fourth quarter, the company reported an operating margin of 31.9%, a slight decrease of one percentage point from the previous year, indicating that its cost structure remains stable.

Earnings Per Share Performance

Tracking long-term changes in earnings per share (EPS) helps gauge whether a company’s growth is translating into higher profitability. Zoetis’s EPS has grown at a compound annual rate of 10.8% over the past five years, outpacing its revenue growth and signaling improved profitability per share.

Several factors have contributed to this EPS growth: while the operating margin dipped this quarter, it has expanded by 1.5 percentage points over five years, and the company’s share count has decreased by 8.4%. These trends benefit shareholders, as higher profitability and share buybacks accelerate EPS gains relative to revenue.

For Q4, Zoetis reported adjusted EPS of $1.48, up from $1.40 a year ago and 5.5% above analyst expectations. Wall Street forecasts full-year EPS of $6.42 for the next 12 months, representing a 6% increase.

Summary and Outlook

Zoetis’s latest results surpassed analyst expectations for both full-year guidance and quarterly EPS, leading to a 4.8% jump in its stock price to $134.82 after the announcement. While the company had a strong quarter, investors should also consider valuation, business fundamentals, and recent performance before making investment decisions.